Funding for this research was provided by:
King Faisal Specialist and Research Centre (RAC 2160 003)
Received: 1 May 2019
Revised: 16 July 2019
Accepted: 26 August 2019
First Online: 23 September 2019
Ethics approval and consent to participate
: All material is original and has not been reproduced from another source, and experiments using animal were approved by KFSHRC animal care and ethics committee.
: Not applicable
: Kilian Kelly is a shareholder and employee of Cynata Therapeutics Limited, Australia, which holds intellectual property rights on the Cymerus iPSC-derived MSCs used in this study. The other authors declare that they have no competing interests.